Auspex To Present at BioCentury's Future Leaders in the Biotech Industry Conference
LA JOLLA, Calif., March 24, 2014 /PRNewswire/ -- Auspex Pharmaceuticals, Inc. (Nasdaq: ASPX), a late clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, today announced that the company will present at BioCentury's Future Leaders in the Biotech Industry conference. The presentation will be delivered by Pratik Shah, Ph.D., President and CEO of Auspex Pharmaceuticals, at 10:30 a.m. EDT on Friday March 28th at the Millennium Broadway Hotel & Conference Center in New York.
A webcast of the presentation will be available through the investor relations section of Auspex Pharmaceutical's website, www.auspexpharma.com. Following the live webcast, a replay will be available through the same section for 30 days.
About Auspex Pharmaceuticals
Auspex Pharmaceuticals is a late clinical stage biopharmaceutical company focused on the development and commercialization of novel medicines for the treatment of orphan diseases. Auspex's pipeline includes product candidates to address unmet medical needs in hyperkinetic movement disorders, such as chorea associated with Huntington's disease, tardive dyskinesia and Tourette syndrome, as well as other orphan indications. Auspex's lead product candidate, SD-809, is in a Phase 3 registration clinical trial for the treatment of chorea (abnormal involuntary movements) associated with Huntington's disease. Auspex has employed its deuterium chemistry approach to optimize other deuterium-containing compounds in its portfolio that are at various stages of development. For further information, please visit the company's website www.auspexpharma.com.
SOURCE Auspex Pharmaceuticals